{
  "hero": {
    "title": "Oncology Interim Analysis",
    "subtitle": "AI-powered statistical analysis and biomarker stratification",
    "time_investment": "‚è±Ô∏è 15-20 minutes ‚Ä¢ Statistical analysis ‚Ä¢ Biomarker insights"
  },
  "trial_overview": {
    "title": "Phase II Oncology Biomarker Trial",
    "subtitle": "Novel Immunotherapy with Biomarker Stratification",
    "description": "Experience how AI processes complex interim analysis results for a Phase II oncology trial with mixed efficacy signals across biomarker subgroups.",
    "key_metrics": [
      "Target Enrollment: 200 patients",
      "Duration: 24 months", 
      "Primary Endpoint: Progression-free survival",
      "Biomarker: PD-L1 expression levels"
    ]
  },
  "analysis_phases": [
    {
      "title": "Interim Analysis Results",
      "description": "AI processing of complex efficacy signals across biomarker subgroups"
    },
    {
      "title": "Statistical Power Analysis",
      "description": "Optimization of sample size and statistical power"
    },
    {
      "title": "Biomarker Stratification",
      "description": "Identification of predictive biomarkers and patient subgroups"
    },
    {
      "title": "Regulatory Pathway Optimization",
      "description": "Strategic planning for regulatory submission and approval"
    }
  ],
  "credibility_indicators": [
    {
      "icon": "üéì",
      "text": "Developed with biostatisticians and oncology experts"
    },
    {
      "icon": "üìä",
      "text": "Based on analysis of 40+ oncology trials and biomarker studies"
    }
  ]
}
